Loading...
This record has been deleted. Since it is linked to a published record, it is available here for reference purposes only.
Click here to view the deleted recordThis document has been updated. This is not the latest published version. Click here to view the latest version of the record.
Living Modified Organism
(LMO)
The image below identifies the LMO through its unique identifier, trade name and a link to this page of the BCH. Click on it to download a larger image on your computer. For help on how to use it go to the LMO quick-links page.
Imojev (Japanese Encephalitis Chimeric Virus Vaccine; JE-CV)
EN
N/A
No
-
Organization:Sanofi-Aventis New Zealand Limited ()Level 8, 56 Cawley Street, Ellerslie, Auckland, 1051Auckland,
PO Box 12851, New ZealandPhone: + 64 09 5801829,Fax: + 64 09 5801811,Email: alan.carter@sanofi.com,
Imojev is a modified live, attenuated, viral vaccine designed to provide protection against Japanese encephalitis. The modified virus is chimeric as a result of replacing the pre-membrane and envelope coding sequences from the yellow fever virus strain 17D with the corresponding sequences from the Japanese encephalitis virus strain SA14-14-2.
EN
The term “Recipient organism” refers to an organism (either already modified or non-modified) that was subjected to genetic modification, whereas “Parental organisms” refers to those that were involved in cross breeding or cell fusion.
-
BCH-ORGA-SCBD-114709-3 Organism Japanese encephalitis virus (JEV SA14-14-2)Viruses
-
BCH-ORGA-SCBD-114710-2 Organism Yellow fever virus (YFV 17D)Viruses
Japanese encephalitis virus strain SA 14-14-2 (vaccine strain)
Yellow fever virus strain 17D (vaccine strain)
EN
Yellow fever virus strain 17D (vaccine strain)
Yellow fever virus strain 17D
EN
- (Gene replacement (Recombinant DNA))
|
0.118 kb
|
|
0.362 kb
|
|
0.500 kb
|
|
1.500 kb
|
|
1.050 kb
|
|
0.671 kb
|
|
0.389 kb
|
|
1.868 kb
|
|
0.377 kb
|
|
0.070 kb
|
|
0.749 kb
|
|
2.714 kb
|
|
0.520 kb
|
Some of these genetic elements may be present as fragments or truncated forms. Please see notes below, where applicable.
-
BCH-GENE-SCBD-114711-2 5' Noncoding region of Yellow fever virus | Yellow fever virus (YFV 17D)5' Untranslated region
-
BCH-GENE-SCBD-114712-2 Anchored core protein C | Yellow fever virus (YFV 17D)Protein coding sequence
-
BCH-GENE-SCBD-114713-1 pre-membrane protein | Japanese encephalitis virus (JEV SA14-14-2)Protein coding sequence
-
BCH-GENE-SCBD-114714-1 Envelope protein | Japanese encephalitis virus (JEV SA14-14-2)Protein coding sequence
-
BCH-GENE-SCBD-114715-1 Nonstructural protein 1 | Yellow fever virus (YFV 17D)Protein coding sequence
-
BCH-GENE-SCBD-114716-1 Nonstructural protein 2A | Yellow fever virus (YFV 17D)Protein coding sequence
-
BCH-GENE-SCBD-114717-1 Nonstructural protein 2B | Yellow fever virus (YFV 17D)Protein coding sequence
-
BCH-GENE-SCBD-114721-2 Nonstructural protein 3 | Yellow fever virus (YFV 17D)Protein coding sequence
-
BCH-GENE-SCBD-114722-1 Nonstructural protein 4A | Yellow fever virus (YFV 17D)Protein coding sequence
-
BCH-GENE-SCBD-114723-1 Peptide 2K | Yellow fever virus (YFV 17D)Protein coding sequence
-
BCH-GENE-SCBD-114724-1 Nonstructural protein 4B | Yellow fever virus (YFV 17D)Protein coding sequence
-
BCH-GENE-SCBD-114725-1 Nonstructural protein 5 | Yellow fever virus (YFV 17D)Protein coding sequence
-
BCH-GENE-SCBD-114726-2 3' Noncoding region of Yellow fever virus | Yellow fever virus (YFV 17D)Terminator
The chimeric virus was created by replacing the pre-membrane and envelope proteins from Yellow fever virus strain 17D (YFV) with the corresponding sequences from Japanese encephalitis virus (JEV) strain SA14-14-2. Since, the viral genome is single stranded, positive RNA, cDNA was synthesized to replace the genes in the viral genome. After creating the chimeric genome, RNA was synthesized from the cDNA and injected into host cells to create chimeric viral particles.
Translation begins from the 5' noncoding region, synthesizing a single, polyprotein before terminating at the 3' noncoding region. Upon translation, nonstructural protein 3 along with nonstructural protein 2B autocatalyze peptide cleavage. The final viral particles contain YFV anchored protein C (ancC), YFV protein C (processed from ancC), JEV pre-membrane protein (prM), JEV protein M (processed from prM), JEV envelope protein, and viral RNA.
Note:
The chimeric virus was created from live, attenuated YFV and JEV vaccine strains and demonstrated a similar lack of virulence of the parental strains. However, the immune response was sufficient to create immunity to wild-type JEV.
EN
Translation begins from the 5' noncoding region, synthesizing a single, polyprotein before terminating at the 3' noncoding region. Upon translation, nonstructural protein 3 along with nonstructural protein 2B autocatalyze peptide cleavage. The final viral particles contain YFV anchored protein C (ancC), YFV protein C (processed from ancC), JEV pre-membrane protein (prM), JEV protein M (processed from prM), JEV envelope protein, and viral RNA.
Note:
The chimeric virus was created from live, attenuated YFV and JEV vaccine strains and demonstrated a similar lack of virulence of the parental strains. However, the immune response was sufficient to create immunity to wild-type JEV.
EN
- Vaccine
EN
EN
- Virus Pathogen Resource - Strain Details for Japanese encephalitis virus Strain SA14-14-2 [ English ]
- Virus Pathogen Resource - Strain Details for Yellow fever virus Strain 17D vaccine [ English ]
- NCBI - YFV genetic sequence [ English ]
- Persistence of Wild-Type Japanese Encephalitis Virus Strains Cross-Neutralization 5 Years After JE-CV Immunization.pdf [ English ]
- Chimeric Live, Attenuated Vaccine against Japanese Encephalitis.pdf [ English ]
| Record type | Field | Record(s) | |
|---|---|---|---|
| Country's Decision or any other Communication | LMO identification | 1 | |
| Risk Assessment generated by a regulatory process | Living modified organism(s) | 1 | |
